First US Branded Ophthalmic Launch A ‘Milestone’ For Sun
India’s biggest drug firm Sun has just launched its first branded ophthalmic product in the US, marking what the company calls “a milestone” in its quest to build scale and seek steady revenue streams in the global specialty drug business.
You may also be interested in...
Xelpros may not be seen as a huge money-spinner, but its approval by the US FDA signals Sun Pharma's expanding interest in the US ophthalmology space. The clearance also potentially indicates that recent compliance issues at the company’s Halol site may not be all-encompassing.
Sun Pharma, India’s biggest drug firm, slid into the red in the first quarter, hit by a hefty legal payout, regulatory woes and a dramatic drop in US sales, and company founder Dilip Shanghvi said while he expected a “gradual improvement” in performance, the outlook remained challenging.
Former Pfizer employee has joined Sun Pharma as it launches ophthalmic drug and expands its specialty portfolio, which includes Phase III monoclonal antibody for treatment of psoriasis.